First Human Trial of Gene Therapy to Reprogram Aged Cells

Life Biosciences treated the first human volunteer on June 9 in a clinical trial testing “partial reprogramming” gene therapy. The study aims to repair damaged optic nerves in patients with glaucoma by activating three specific genes to restore youthful cell function, according to the company.

How does partial reprogramming work to restore vision?

The therapy targets retinal ganglion cells in the optic nerve, which typically do not regenerate in adults. Life Biosciences uses a virus to deliver three genes that prompt aged cells to behave like younger cells without fully converting them into stem cells.

This approach follows 2020 research from David Sinclair’s laboratory at Harvard Medical School. That study demonstrated that activating these three genes triggered nerve regeneration and reversed vision loss in both aged and glaucomatous mice.

Did You Know? A 2020 study by David Sinclair’s lab at Harvard Medical School showed that activating three specific genes could trigger nerve regeneration and reverse vision loss in mice with glaucoma.

Why is the eye the first target for this therapy?

The eye provides a safer environment for testing high-risk genetic technology. Matt Kaeberlein, co-founder of Seattle-based Optispan, stated that the eye is a safer starting point because vital risks are lower compared to other organs.

While the technology shows potential, Kaeberlein warned that it is still in early stages and carries a risk of serious side effects. Specifically, some scientists worry that reprogramming cells could lead to uncontrolled growth or cancer.

Expert Insight: Samantha Carter notes that the primary tension in this trial is the balance between the potential for organ regeneration and the risk of oncogenesis. By using the eye as a controlled environment, researchers can test the efficacy of “biological time reversal” while mitigating systemic risks to the patient.

How is the gene therapy controlled for safety?

The system includes a chemical “on-off” switch to prevent cells from remaining in a reprogrammed state too long. The genes are activated by the antibiotic doxycycline; once the medication is stopped, the genes turn off.

Dr David Sinclair's Reprogramming Tech in Human Trials

Sharon Rosenzweig-Lipson, chief scientific officer at Life Biosciences, stated that this mechanism provides significant control. She noted that it allows the company to ensure genes do not remain active longer than necessary.

What happens next in the clinical trial?

Life Biosciences plans to treat up to 12 patients with glaucoma. The company may also include participants with NAION, a condition causing sudden and severe optic nerve damage, in later stages of the study.

The company is also testing this method in other models, including liver diseases. However, Pete Williams of the Centre for Eye Research Australia warned that high public expectations are risky, as a failure could negatively impact future research.

Frequently Asked Questions

What is partial reprogramming?

It is a method that uses three genes to move aged cells toward a younger biological state without turning them into stem cells, allowing them to retain their original functions.

How is the treatment delivered to the patient?

The therapy uses a virus, a common tool in gene therapy, to transport the specific genes into the target cells.

Is this therapy intended for full-body rejuvenation?

No. Life Biosciences stated they do not currently aim for “whole-body rejuvenation” and are instead focusing on individual age-related diseases.

How do you view the trade-off between the potential for organ regeneration and the risk of uncontrolled cell growth?